Laurence Lamant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laurence Lamant has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Camille Laurent
Laboratoire d'Excellence TOUCAN, Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Institut Universitaire Cancer‐Oncopole, CHU Toulouse Toulouse France
2 shared publications Georges Delsol
Laboratoire d'Anatomie Pathologique, CHU Purpan, Toulouse, F-31300, France
2 shared publicationsA Berrebi
Fédération de Gynécologie-Obstétrique, CHU Paule de Viguier, Toulouse, France
1 shared publicationAnna Kruczynski
Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, Cedex 4, France
1 shared publicationAtsuko Nakagawa
1 shared publication- Audrey Mauguen
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
1 shared publication
Latest Publications
- 24 September 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 16 (11) , 1127-1138
Anaplastic lymphoma kinase as a therapeutic target
(2012). Anaplastic lymphoma kinase as a therapeutic target. Expert Opinion on Therapeutic Targets: Vol. 16, No. 11, pp. 1127-1138.
- 24 September 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 16 (11) , 1127-1138
Anaplastic lymphoma kinase as a therapeutic target
(2012). Anaplastic lymphoma kinase as a therapeutic target. Expert Opinion on Therapeutic Targets: Vol. 16, No. 11, pp. 1127-1138.
- 10 December 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (35) , 4669-4676
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study
Purpose: The prognostic value of pathologic characteristics of childhood ALK-positive anaplastic large-cell lymphomas (ALCL), such as histologic subtypes, immunophenotype, and presence of the t(2;5) translocation or its variants, was assessed. Patients and Methods: All 375 patients with systemic ALK-positive ALCL included in an international trial launched by the European Intergroup for Childhood Non-Hodgkin's Lymphoma were reviewed by an international panel of pathologists based on conventional hematoxylin and eosin–stained and immunostained sections and classified according to the 2001 WHO classification. Results: A small-cell (SC) or lymphohistiocytic (LH) component was observed in 114 (32%) of 361 patients, whereas ALCL of common type was diagnosed in 235 (65%) of 361 patients. Regarding the histologic subtyping of patients within the two categories of ALCL (with v without SC/LH component), the concordance between the national and international reviews was quite good, with a κ index equal to 0.67 (95% CI, 0.57 to 0.75). The presence of an SC/LH component was significantly associated with a high risk of failure (hazard ratio [HR], 2.0; 95% CI, 1.3 to 3.0; P = .002) in the multivariate analysis controlling for clinical characteristics, as well as the perivascular pattern (HR, 1.7; 95% CI, 1.1 to 2.7; P = .01), whereas CD3 positivity was significantly associated with a high risk of failure only in univariate analysis. Conclusion: Our study, which to our knowledge includes the largest series of childhood systemic ALK-positive ALCL so far, demonstrates the adverse prognostic value of SC and/or LH morphologic features. Combining these histologic characteristics with other biologic or clinical factors might have a high potential for future risk stratification and treatment.
- 10 December 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (35) , 4669-4676
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study
Purpose: The prognostic value of pathologic characteristics of childhood ALK-positive anaplastic large-cell lymphomas (ALCL), such as histologic subtypes, immunophenotype, and presence of the t(2;5) translocation or its variants, was assessed. Patients and Methods: All 375 patients with systemic ALK-positive ALCL included in an international trial launched by the European Intergroup for Childhood Non-Hodgkin's Lymphoma were reviewed by an international panel of pathologists based on conventional hematoxylin and eosin–stained and immunostained sections and classified according to the 2001 WHO classification. Results: A small-cell (SC) or lymphohistiocytic (LH) component was observed in 114 (32%) of 361 patients, whereas ALCL of common type was diagnosed in 235 (65%) of 361 patients. Regarding the histologic subtyping of patients within the two categories of ALCL (with v without SC/LH component), the concordance between the national and international reviews was quite good, with a κ index equal to 0.67 (95% CI, 0.57 to 0.75). The presence of an SC/LH component was significantly associated with a high risk of failure (hazard ratio [HR], 2.0; 95% CI, 1.3 to 3.0; P = .002) in the multivariate analysis controlling for clinical characteristics, as well as the perivascular pattern (HR, 1.7; 95% CI, 1.1 to 2.7; P = .01), whereas CD3 positivity was significantly associated with a high risk of failure only in univariate analysis. Conclusion: Our study, which to our knowledge includes the largest series of childhood systemic ALK-positive ALCL so far, demonstrates the adverse prognostic value of SC and/or LH morphologic features. Combining these histologic characteristics with other biologic or clinical factors might have a high potential for future risk stratification and treatment.
- Open Access
- 12 August 2011
- Published by Springer Nature in Leukemia
- Vol. 26 (1) , 188-190
Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns
- 12 August 2011
- Published by Springer Nature in Leukemia
- Vol. 26 (1) , 188-190
Open AccessCirculating t(2;5)-positive cells can be detected in cord blood of healthy newborns
- 1 November 2007
- Vol. 27, 3441-9
Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers.
Identification of markers associated with melanoma progression is crucial to identify new prognostic and/or therapeutic targets. By using DNA microarrays, two human melanoma cell lines, M4Be and Tw12, derived from the same tumor, but with different metastatic potential, were profiled. Western blot of cell lines, immunohistochemistry on melanoma biopsies and in silico analyses validated and extended our results. Thirty-six clones were differentially-expressed between the two cell lines, representing 33 named genes and 2 expressed sequence tags. The most up-regulated gene in the strongly metastatic clone Tw12 was CD10. Protein analysis with anti-CD1O antibody confirmed this finding in cell lines and clinical samples with expression being more frequent in metastatic compared to primary tumors. Many up-regulated genes were involved in angiogenesis, invasion, growth and apoptosis. Down-regulated genes included tumor suppressor genes and those were involved in differentiation. We identified several genes the expression of which is associated with metastatic progression in human melanoma cells. Although further analyses are warranted to clarify their exact role in tumor progression, they might lead to new prognostic markers and/or molecular therapeutic targets in metastatic melanoma.
- 1 November 2007
- Vol. 27, 3441-9
Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers.
Identification of markers associated with melanoma progression is crucial to identify new prognostic and/or therapeutic targets. By using DNA microarrays, two human melanoma cell lines, M4Be and Tw12, derived from the same tumor, but with different metastatic potential, were profiled. Western blot of cell lines, immunohistochemistry on melanoma biopsies and in silico analyses validated and extended our results. Thirty-six clones were differentially-expressed between the two cell lines, representing 33 named genes and 2 expressed sequence tags. The most up-regulated gene in the strongly metastatic clone Tw12 was CD10. Protein analysis with anti-CD1O antibody confirmed this finding in cell lines and clinical samples with expression being more frequent in metastatic compared to primary tumors. Many up-regulated genes were involved in angiogenesis, invasion, growth and apoptosis. Down-regulated genes included tumor suppressor genes and those were involved in differentiation. We identified several genes the expression of which is associated with metastatic progression in human melanoma cells. Although further analyses are warranted to clarify their exact role in tumor progression, they might lead to new prognostic markers and/or molecular therapeutic targets in metastatic melanoma.